Ernesto Scibona
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ernesto Scibona has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Ana Vukolic
11 shared publicationsAnja Irmisch
11 shared publicationsBenchun Miao
11 shared publicationsChaoran Cheng
11 shared publications- Christophe D. Chabbert
Roche Innovation Center Zurich, Switzerland
11 shared publications - Daniela Müllhaupt
Department of Biology, Institute of Molecular Health Sciences, Eidgenössische Technische Hochschule Zürich (ETH) Zurich, Zurich, Switzerland
11 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Contains Supplementary materials and methods, Supplementary Figures S1-S9, Table S2, Table S4, Supplemental References Figure S1, related to Figure 1. Cell surface marker screening of A375P cells treated with vehicle (DMSO) or PLX. Figure S2, related to Figure 1. CD36 is a biomarker of the early stage of MAPK inhibition in melanoma. Figure S3, related to Figure 1. MAPK inhibition induces and maintains the CD36+ population in melanoma cells Figure S4, related to Figure 2. MAPKi induce the expression of genes involved in lipid catabolism in BRAFV600E melanomas. Figure S5, related to Figure 3. MAPK inhibition decreased the glycolytic flux in BRAF-mutated melanoma cells. Figure S6, related to Figure 4. Phenotypic and metabolic characterization of CD36 WT, CD36 KO, CD36+ and CD36- A375P cells. Figure S7, related to Figure 5. PPARα does not regulate CD36 expression. Figure S8, related to Figure 6. Role of glycolysis and FAO inhibitors in proliferation and resistance to MAPKi Figure S9, related to Figure 6. Effects of MAPK, glycolysis and FAO inhibition on mouse and tumor weight. Table S2, related to Figure 1, Figure 3, Figure 6, Figure S3 and Figure S6. Primer list. Table S4, related to Figure 1 and Figure S2. Cell lines, their mutational status and their responsiveness to MAPK inhibitors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Contains Supplementary materials and methods, Supplementary Figures S1-S9, Table S2, Table S4, Supplemental References Figure S1, related to Figure 1. Cell surface marker screening of A375P cells treated with vehicle (DMSO) or PLX. Figure S2, related to Figure 1. CD36 is a biomarker of the early stage of MAPK inhibition in melanoma. Figure S3, related to Figure 1. MAPK inhibition induces and maintains the CD36+ population in melanoma cells Figure S4, related to Figure 2. MAPKi induce the expression of genes involved in lipid catabolism in BRAFV600E melanomas. Figure S5, related to Figure 3. MAPK inhibition decreased the glycolytic flux in BRAF-mutated melanoma cells. Figure S6, related to Figure 4. Phenotypic and metabolic characterization of CD36 WT, CD36 KO, CD36+ and CD36- A375P cells. Figure S7, related to Figure 5. PPARα does not regulate CD36 expression. Figure S8, related to Figure 6. Role of glycolysis and FAO inhibitors in proliferation and resistance to MAPKi Figure S9, related to Figure 6. Effects of MAPK, glycolysis and FAO inhibition on mouse and tumor weight. Table S2, related to Figure 1, Figure 3, Figure 6, Figure S3 and Figure S6. Primer list. Table S4, related to Figure 1 and Figure S2. Cell lines, their mutational status and their responsiveness to MAPK inhibitors.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S3, related to Figure 1 and Figure S1
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S3, related to Figure 1 and Figure S1
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S5, related to Figure S5C
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S5, related to Figure S5C
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S1 contains antibody details of the LEGENDScreen Human PE Kit from Biolegend
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S1 contains antibody details of the LEGENDScreen Human PE Kit from Biolegend
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Purpose:Treatment of BRAFV600E-mutant melanomas with MAPK inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand nonmutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities of melanomas treated with MAPKi, we focused on the initial response phase during treatment with MAPKi.Experimental Design:By screening proteins expressed on the cell surface of melanoma cells, we identified the fatty acid transporter CD36 as the most consistently upregulated protein upon short-term treatment with MAPKi. We further investigated the effects of MAPKi on fatty acid metabolism using in vitro and in vivo models and analyzing patients' pre- and on-treatment tumor specimens.Results:Melanoma cells treated with MAPKi displayed increased levels of CD36 and of PPARα-mediated and carnitine palmitoyltransferase 1A (CPT1A)-dependent fatty acid oxidation (FAO). While CD36 is a useful marker of melanoma cells during adaptation and drug-tolerant phases, the upregulation of CD36 is not functionally involved in FAO changes that characterize MAPKi-treated cells. Increased FAO is required for BRAFV600E-mutant melanoma cells to survive under the MAPKi-induced metabolic stress prior to acquiring drug resistance. The upfront and concomitant inhibition of FAO, glycolysis, and MAPK synergistically inhibits tumor cell growth in vitro and in vivo.Conclusions:Thus, we identified a clinically relevant therapeutic approach that has the potential to improve initial responses and to delay acquired drug resistance of BRAFV600E-mutant melanoma.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Purpose:Treatment of BRAFV600E-mutant melanomas with MAPK inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand nonmutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities of melanomas treated with MAPKi, we focused on the initial response phase during treatment with MAPKi.Experimental Design:By screening proteins expressed on the cell surface of melanoma cells, we identified the fatty acid transporter CD36 as the most consistently upregulated protein upon short-term treatment with MAPKi. We further investigated the effects of MAPKi on fatty acid metabolism using in vitro and in vivo models and analyzing patients' pre- and on-treatment tumor specimens.Results:Melanoma cells treated with MAPKi displayed increased levels of CD36 and of PPARα-mediated and carnitine palmitoyltransferase 1A (CPT1A)-dependent fatty acid oxidation (FAO). While CD36 is a useful marker of melanoma cells during adaptation and drug-tolerant phases, the upregulation of CD36 is not functionally involved in FAO changes that characterize MAPKi-treated cells. Increased FAO is required for BRAFV600E-mutant melanoma cells to survive under the MAPKi-induced metabolic stress prior to acquiring drug resistance. The upfront and concomitant inhibition of FAO, glycolysis, and MAPK synergistically inhibits tumor cell growth in vitro and in vivo.Conclusions:Thus, we identified a clinically relevant therapeutic approach that has the potential to improve initial responses and to delay acquired drug resistance of BRAFV600E-mutant melanoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Purpose:Treatment of BRAFV600E-mutant melanomas with MAPK inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand nonmutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities of melanomas treated with MAPKi, we focused on the initial response phase during treatment with MAPKi.Experimental Design:By screening proteins expressed on the cell surface of melanoma cells, we identified the fatty acid transporter CD36 as the most consistently upregulated protein upon short-term treatment with MAPKi. We further investigated the effects of MAPKi on fatty acid metabolism using in vitro and in vivo models and analyzing patients' pre- and on-treatment tumor specimens.Results:Melanoma cells treated with MAPKi displayed increased levels of CD36 and of PPARα-mediated and carnitine palmitoyltransferase 1A (CPT1A)-dependent fatty acid oxidation (FAO). While CD36 is a useful marker of melanoma cells during adaptation and drug-tolerant phases, the upregulation of CD36 is not functionally involved in FAO changes that characterize MAPKi-treated cells. Increased FAO is required for BRAFV600E-mutant melanoma cells to survive under the MAPKi-induced metabolic stress prior to acquiring drug resistance. The upfront and concomitant inhibition of FAO, glycolysis, and MAPK synergistically inhibits tumor cell growth in vitro and in vivo.Conclusions:Thus, we identified a clinically relevant therapeutic approach that has the potential to improve initial responses and to delay acquired drug resistance of BRAFV600E-mutant melanoma.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Purpose:Treatment of BRAFV600E-mutant melanomas with MAPK inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand nonmutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities of melanomas treated with MAPKi, we focused on the initial response phase during treatment with MAPKi.Experimental Design:By screening proteins expressed on the cell surface of melanoma cells, we identified the fatty acid transporter CD36 as the most consistently upregulated protein upon short-term treatment with MAPKi. We further investigated the effects of MAPKi on fatty acid metabolism using in vitro and in vivo models and analyzing patients' pre- and on-treatment tumor specimens.Results:Melanoma cells treated with MAPKi displayed increased levels of CD36 and of PPARα-mediated and carnitine palmitoyltransferase 1A (CPT1A)-dependent fatty acid oxidation (FAO). While CD36 is a useful marker of melanoma cells during adaptation and drug-tolerant phases, the upregulation of CD36 is not functionally involved in FAO changes that characterize MAPKi-treated cells. Increased FAO is required for BRAFV600E-mutant melanoma cells to survive under the MAPKi-induced metabolic stress prior to acquiring drug resistance. The upfront and concomitant inhibition of FAO, glycolysis, and MAPK synergistically inhibits tumor cell growth in vitro and in vivo.Conclusions:Thus, we identified a clinically relevant therapeutic approach that has the potential to improve initial responses and to delay acquired drug resistance of BRAFV600E-mutant melanoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S1 contains antibody details of the LEGENDScreen Human PE Kit from Biolegend
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S1 contains antibody details of the LEGENDScreen Human PE Kit from Biolegend
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S3, related to Figure 1 and Figure S1
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S3, related to Figure 1 and Figure S1
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S5, related to Figure S5C
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Table S5, related to Figure S5C
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Contains Supplementary materials and methods, Supplementary Figures S1-S9, Table S2, Table S4, Supplemental References Figure S1, related to Figure 1. Cell surface marker screening of A375P cells treated with vehicle (DMSO) or PLX. Figure S2, related to Figure 1. CD36 is a biomarker of the early stage of MAPK inhibition in melanoma. Figure S3, related to Figure 1. MAPK inhibition induces and maintains the CD36+ population in melanoma cells Figure S4, related to Figure 2. MAPKi induce the expression of genes involved in lipid catabolism in BRAFV600E melanomas. Figure S5, related to Figure 3. MAPK inhibition decreased the glycolytic flux in BRAF-mutated melanoma cells. Figure S6, related to Figure 4. Phenotypic and metabolic characterization of CD36 WT, CD36 KO, CD36+ and CD36- A375P cells. Figure S7, related to Figure 5. PPARα does not regulate CD36 expression. Figure S8, related to Figure 6. Role of glycolysis and FAO inhibitors in proliferation and resistance to MAPKi Figure S9, related to Figure 6. Effects of MAPK, glycolysis and FAO inhibition on mouse and tumor weight. Table S2, related to Figure 1, Figure 3, Figure 6, Figure S3 and Figure S6. Primer list. Table S4, related to Figure 1 and Figure S2. Cell lines, their mutational status and their responsiveness to MAPK inhibitors.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Contains Supplementary materials and methods, Supplementary Figures S1-S9, Table S2, Table S4, Supplemental References Figure S1, related to Figure 1. Cell surface marker screening of A375P cells treated with vehicle (DMSO) or PLX. Figure S2, related to Figure 1. CD36 is a biomarker of the early stage of MAPK inhibition in melanoma. Figure S3, related to Figure 1. MAPK inhibition induces and maintains the CD36+ population in melanoma cells Figure S4, related to Figure 2. MAPKi induce the expression of genes involved in lipid catabolism in BRAFV600E melanomas. Figure S5, related to Figure 3. MAPK inhibition decreased the glycolytic flux in BRAF-mutated melanoma cells. Figure S6, related to Figure 4. Phenotypic and metabolic characterization of CD36 WT, CD36 KO, CD36+ and CD36- A375P cells. Figure S7, related to Figure 5. PPARα does not regulate CD36 expression. Figure S8, related to Figure 6. Role of glycolysis and FAO inhibitors in proliferation and resistance to MAPKi Figure S9, related to Figure 6. Effects of MAPK, glycolysis and FAO inhibition on mouse and tumor weight. Table S2, related to Figure 1, Figure 3, Figure 6, Figure S3 and Figure S6. Primer list. Table S4, related to Figure 1 and Figure S2. Cell lines, their mutational status and their responsiveness to MAPK inhibitors.